News for CardieX Limited (AMDHF)

SYDNEY, Sept. 26, 2024 /PRNewswire/ -- Cardiex Limited (ASX: CDX), a global health technology company focused on cardiovascular diagnostics and arterial health solutions, today announced the publication of a peer-reviewed study validating its innovative method for measuring central aortic pressure-an important indicator of heart health-using a noninvasive fingertip sensor. The study, co-authored by Cardiex's team, was published in the respected journal Pulse.

/PRNewswire/ -- ATCOR Medical, a subsidiary of CardieX and developer of innovative medical devices and digital health solutions to optimize hypertension...

At the end of a crazy week, it's the goldies out in front again, more than 3.0% better than the ASX benchmark's -1.09% fizzer.

Some ASX stocks to go to war with, some very bullish gold hedges, and who won the ASX in April?

After a solid +0.8% start, the ASX sagged to a 0.35% close, while Small Cappers Lincoln Minerals and Optima went flying on no news at all.

The healthcare sector is ripe for disruption and artificial intelligence will play a big part in future drug discovery.

CardieX (ASX:CDX) equities research shop MST Access has upgraded its valuation after they received regulatory clearance for their monitor.

CardieX Limited(ASX:CDX) world’s first customisable vascular biometric monitor receives regulatory clearance to provide heart health metrics.

The ASX rallied from a -0.5% dip to hit lunch flat, CPI data hits market expectations while Brookfield's oil reserve looks better than ever.

Like Wall Street, local markets ended the week lower, but Japanese stocks look strong and the EU benchmark is at bold 14 month highs.

Colossal Biosciences’ plans to bring the Tasmanian tiger and woolly mammoth back to life, but now it’s also betting on the iconic dodo.

The FDA declined regulate CBD-based supplements and food citing safety reasons, but the CBD index keeps going up.

Japanese startup OUI Inc says it is on a mission to halve the world's blindness with its smartphone-based device.

Moderna’s stock price rose in late December after the company revealed that a vaccine for melanoma showed encouraging results.

The ASX is down 0.5% so far, Flynn Gold has gone zooming and anyone who reckons their boss is too tough needs to read this today.

The ASX struggled bravely to a 0.5% gain for the day, a couple of big players got themselves in big trouble and Patriot Lithium went bonkers.

The US FDA has just approved the world’s most expensive drug. CSL Behring’s hemophilia B gene therapy costs US$3.5m a dose.

ASX health stocks have fallen out of favour in 2022 with a a rotation out of growth into value sectors but could it also do with better PR?

Four ASX healthcare stocks have been rated as a ‘Strong Buy' by Morningstar’s consensus of brokers, making them hot tips.